Literature DB >> 34319596

Circulating regulatory T cells in adult-onset Still's disease: Focusing on their plasticity and stability.

Yasuhiro Shimojima1, Takanori Ichikawa1, Dai Kishida1, Ryota Takamatsu1, Yoshiki Sekijima1.   

Abstract

We investigated the characteristics of regulatory T cells in adult-onset Still's disease (AOSD) with a focus on their plasticity, stability and relationship to disease severity. The proportion of circulating CD4+ CD25+ forkhead box protein 3 (FoxP3+ ) cells (Tregs ) and intracellular expression of effector cytokines, including interferon (IFN)-γ, interleukin (IL)-17 and IL-4, was analysed in 27 untreated patients with AOSD (acute AOSD), 11 of the 27 patients after remission and 16 healthy controls (HC) using flow cytometry. The suppressive ability of Tregs was also evaluated. Regression analyses of the results were performed. The proportion of Tregs was significantly lower in patients with acute AOSD than in the HC. The expression levels of IFN-γ, IL-17 and IL-4 in Tregs were significantly increased in patients with acute AOSD. IFN-γ and IL-4 expression levels were inversely correlated with the proportion of Tregs and positively correlated with serum ferritin levels. Decreased expression of FoxP3 in CD4+ CD25+ cells, which was correlated with increased expression of IL-17, and impaired suppressive function were observed in Tregs in acute AOSD. However, these aberrant findings in Tregs , including the reduced circulating proportion and functional ability and altered intracellular expression levels of cytokines and FoxP3, were significantly improved after remission. In acute AOSD, Tregs show plastic changes, including effector cytokine production and reductions in their proportion and functional activity. IFN-γ and IL-4 expression levels in Tregs may be associated with disease severity. Also, down-regulation of FoxP3 may be related to IL-17 expression in Tregs . Importantly, the stability of Tregs can be restored in remission.
© 2021 British Society for Immunology.

Entities:  

Keywords:  adult-onset Still’s disease; effector cytokines; helper T cell-related cytokines; plasticity; regulatory T cells

Mesh:

Substances:

Year:  2021        PMID: 34319596      PMCID: PMC8506130          DOI: 10.1111/cei.13648

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  53 in total

1.  Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation.

Authors:  Petra Hoffmann; Tina J Boeld; Ruediger Eder; Jochen Huehn; Stefan Floess; Georg Wieczorek; Sven Olek; Wolfgang Dietmaier; Reinhard Andreesen; Matthias Edinger
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

Review 2.  Adult-onset Still's disease.

Authors:  Mathieu Gerfaud-Valentin; Yvan Jamilloux; Jean Iwaz; Pascal Sève
Journal:  Autoimmun Rev       Date:  2014-03-19       Impact factor: 9.754

Review 3.  Phenotypical and functional specialization of FOXP3+ regulatory T cells.

Authors:  Daniel J Campbell; Meghan A Koch
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

4.  Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy.

Authors:  Magali Noval Rivas; Oliver T Burton; Petra Wise; Louis-Marie Charbonnier; Peter Georgiev; Hans C Oettgen; Rima Rachid; Talal A Chatila
Journal:  Immunity       Date:  2015-03-10       Impact factor: 31.745

5.  Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.

Authors:  Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Tomoki Nakashima; Masatsugu Oh-hora; Tatsuhiko Kodama; Sakae Tanaka; Jeffrey A Bluestone; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

Review 6.  Phenotypical characterization of regulatory T cells in humans and rodents.

Authors:  A L Rodríguez-Perea; E D Arcia; C M Rueda; P A Velilla
Journal:  Clin Exp Immunol       Date:  2016-08-01       Impact factor: 4.330

7.  Elevated serum levels of free interleukin-18 in adult-onset Still's disease.

Authors:  Charlotte Girard; Jürgen Rech; Michael Brown; Danièle Allali; Pascale Roux-Lombard; François Spertini; Eduardo J Schiffrin; Georg Schett; Bernhard Manger; Sylvette Bas; Greg Del Val; Cem Gabay
Journal:  Rheumatology (Oxford)       Date:  2016-09-10       Impact factor: 7.580

8.  Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.

Authors:  Hans J P M Koenen; Ruben L Smeets; Paul M Vink; Esther van Rijssen; Annemieke M H Boots; Irma Joosten
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

9.  Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease.

Authors:  D Y Chen; J L Lan; F J Lin; T Y Hsieh; M C Wen
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

10.  Genetic and epigenetic variation in the lineage specification of regulatory T cells.

Authors:  Aaron Arvey; Joris van der Veeken; George Plitas; Stephen S Rich; Patrick Concannon; Alexander Y Rudensky
Journal:  Elife       Date:  2015-10-28       Impact factor: 8.140

View more
  3 in total

Review 1.  Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.

Authors:  Shijia Rao; Lemuel Shui-Lun Tsang; Ming Zhao; Wei Shi; Qianjin Lu
Journal:  Front Med (Lausanne)       Date:  2022-08-22

Review 2.  Activation mechanisms of monocytes/macrophages in adult-onset Still disease.

Authors:  Hiroto Tsuboi; Seiji Segawa; Mizuki Yagishita; Hirofumi Toko; Fumika Honda; Ayako Kitada; Haruka Miki; Ayako Ohyama; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

3.  Circulating regulatory T cells in adult-onset Still's disease: Focusing on their plasticity and stability.

Authors:  Yasuhiro Shimojima; Takanori Ichikawa; Dai Kishida; Ryota Takamatsu; Yoshiki Sekijima
Journal:  Clin Exp Immunol       Date:  2021-08-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.